Galderma Group AG: directors' dealings · Switzerland · SIX SER

About Galderma Group AG

Galderma Group AG is a global dermatology specialist listed on the SIX Swiss Exchange (SMI/SPI) in Switzerland under the ticker PY3.F. The company positions itself as a pure-play dermatology category leader, with an integrated portfolio spanning injectable aesthetics, dermatological skincare, and therapeutic dermatology. Founded in 1981, Galderma has built its franchise around skin health and has evolved into a premium, science-led platform with broad international reach. Its headquarters are in Zug, Switzerland, and in 2025 the group also strengthened its operational footprint with a new U.S. headquarters in Miami, underlining the strategic importance of the American market. ([galderma.com](https://www.galderma.com/annual-report-2024?utm_source=openai)) Operationally, Galderma is organized around three core business lines. In injectable aesthetics, the company markets well-established brands such as Dysport/Azzalure and Alluzience in neuromodulators, alongside Restylane and Sculptra in hyaluronic acid fillers and biostimulators. In dermatological skincare, Cetaphil is one of the flagship consumer brands, complemented by Alastin. In therapeutic dermatology, Galderma addresses chronic and medically significant conditions including acne, atopic dermatitis, and prurigo nodularis, with newer assets such as Nemluvio expanding the company’s treatment footprint. This mix gives the group a diversified revenue base and multiple growth vectors across medical and consumer channels. ([galderma.com](https://www.galderma.com/annual-report-2024?utm_source=openai)) Galderma’s competitive position is built on a combination of scientific credibility, a well-recognized brand portfolio, and exposure to structurally attractive dermatology markets. Management emphasizes the breadth of its offering and the depth of its innovation pipeline as key differentiators versus smaller, more narrowly focused competitors. Geographically, the company is truly global, with commercial presence across North America, Europe, Asia-Pacific, and international markets, while the U.S. remains a major earnings and growth engine. Recent launches and line extensions reinforce the company’s premiumization strategy and its ability to expand market share across both physician-led and consumer-led categories. ([galderma.com](https://www.galderma.com/our-strategy?utm_source=openai)) Recent milestones have been especially important for the equity story. In 2024, Galderma completed its initial public offering on the SIX Swiss Exchange on March 22, described by the company as the largest IPO in Switzerland since 2017. Full-year 2024 results showed solid growth, and 2025 brought further acceleration, including record sales and growing momentum from Nemluvio, Relfydess, and Sculptra in China. That momentum carried into early 2026, when the company reported strong first-quarter sales growth. For investors, Galderma combines defensive healthcare exposure with above-market organic growth potential and meaningful pipeline catalysts, making it an important Swiss listed healthcare name to watch. ([galderma.com](https://www.galderma.com/annual-report-2024?utm_source=openai))